Meridian Bioscience Beats on Both Top and Bottom Lines

Meridian Bioscience (NAS: VIVO) reported earnings on Jan. 23. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q1), Meridian Bioscience beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.


Margins expanded across the board.

Revenue details
Meridian Bioscience chalked up revenue of $45.4 million. The eight analysts polled by S&P Capital IQ anticipated sales of $44.4 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $40.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.20. The 10 earnings estimates compiled by S&P Capital IQ predicted $0.19 per share. GAAP EPS of $0.20 for Q1 were 25% higher than the prior-year quarter's $0.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 63.5%, 210 basis points better than the prior-year quarter. Operating margin was 28.9%, 340 basis points better than the prior-year quarter. Net margin was 18.7%, 240 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $48.7 million. On the bottom line, the average EPS estimate is $0.23.

Next year's average estimate for revenue is $189.4 million. The average EPS estimate is $0.87.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 463 members out of 475 rating the stock outperform, and 12 members rating it underperform. Among 118 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 115 give Meridian Bioscience a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $20.43.

Looking for alternatives to Meridian Bioscience? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.

The article Meridian Bioscience Beats on Both Top and Bottom Lines originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Learn about investing from the comfort of your own home.

Portfolio Basics

Take the first steps to building your portfolio.

View Course »

Investment Strategies

Learn the strategies you need to build a winning portfolio

View Course »